Advertisement

Long-Term Sequelae of Polycystic Ovary Syndrome

Association With Insulin Resistance and the Metabolic Syndrome
  • Richard S. Legro
Chapter
Part of the Contemporary Endocrinology book series (COE)

Abstract

Insulin resistance is associated with reproductive abnormalities in women with polycystic ovary syndrome (PCOS) including hyperandrogenemia, anovulation, and polycystic ovaries, as well as long-term risk for developing diabetes and most likely also for cardiovascular disease (CVD) and endometrial cancer. There is emerging evidence of increased subclinical CVD in women with PCOS. But it may not be apparent until the perimenopause. Currently there are scant data that markers of insulin resistance predict response to treatment. Therefore, the role of these markers in selecting and following response to specific treatments is uncertain.

Further research that examines the long-term effects of improving insulin resistance on such important clinical endpoints as the development of diabetes, overt CVD, and endometrial cancer are needed.

Key Words

PCOS Insulin resistance metabolic syndrome cardiovascular disease endometrial carcinoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstetricia et Gynecologica Scandinavica 1992;71:599–604.CrossRefPubMedGoogle Scholar
  2. 2.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–359.CrossRefPubMedGoogle Scholar
  3. 3.
    Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289–2304.CrossRefPubMedGoogle Scholar
  4. 4.
    Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006–4011.CrossRefPubMedGoogle Scholar
  5. 5.
    Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929–1935.CrossRefPubMedGoogle Scholar
  6. 6.
    Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2006;91:48–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Korhonen S, Hippelainen M, Niskanen L, Vanhala M, Saarikoski S. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. Am J Obstet Gynecol 2001;184:289–296.CrossRefPubMedGoogle Scholar
  8. 8.
    Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–146.CrossRefPubMedGoogle Scholar
  9. 9.
    Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165–169.CrossRefPubMedGoogle Scholar
  10. 10.
    Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:66–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74 yr. Diabetes 1987;36:523–534.CrossRefPubMedGoogle Scholar
  12. 12.
    Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–2749.CrossRefPubMedGoogle Scholar
  13. 13.
    Pasquali R, Pelusi C, Ragazzini C, Hasanaj R, Gambineri A. Glucose tolerance, insulin secretion and insulin sensitivity in polycystic ovary syndrome. JOP 2002;3:1–7.PubMedGoogle Scholar
  14. 14.
    Kjos SL, Peters RK, Xiang A, Henry OA, Montoro M, Buchanan TA. Predicting future diabetes in Latino women with gestational diabetes. Utility of early postpartum glucose tolerance testing. Diabetes 1995;44:586–591.CrossRefPubMedGoogle Scholar
  15. 15.
    Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001;16:1995–1998.CrossRefPubMedGoogle Scholar
  16. 16.
    Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005;90:3236–3242.CrossRefPubMedGoogle Scholar
  17. 17.
    Legro RS. Polycystic ovary syndrome and cardioivascular disease: A premature association? Endocr Rev 2003;24:302–312.CrossRefPubMedGoogle Scholar
  18. 18.
    Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001;86:4666–4673.CrossRefPubMedGoogle Scholar
  19. 19.
    Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21:1426–1431.CrossRefPubMedGoogle Scholar
  20. 20.
    Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000;15:24–28.CrossRefPubMedGoogle Scholar
  21. 21.
    Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000;73:724–729.CrossRefPubMedGoogle Scholar
  22. 22.
    Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821–826.PubMedGoogle Scholar
  23. 23.
    Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:111–133.CrossRefPubMedGoogle Scholar
  24. 24.
    Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785–789.CrossRefPubMedGoogle Scholar
  25. 25.
    Loucks TL, Talbott EO, McHugh KP, Keelan M, Berga SL, Guzick DS. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome? Fertil Steril 2000;74:547–552.CrossRefPubMedGoogle Scholar
  26. 26.
    Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87:2013–2037.CrossRefPubMedGoogle Scholar
  27. 27.
    Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51:581–586.CrossRefPubMedGoogle Scholar
  28. 28.
    Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000;3:101–105.CrossRefGoogle Scholar
  29. 29.
    Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414–2421.PubMedGoogle Scholar
  30. 30.
    Vryonidou A, Papatheodorou A, Tavridou A, et al. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2740–2746.CrossRefPubMedGoogle Scholar
  31. 31.
    Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2562–2568.CrossRefPubMedGoogle Scholar
  32. 32.
    Nagamani M, Hannigan EV, Dinh TV, Stuart CA. Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. J Clin Endocrinol Metab 1988;67:144–148.CrossRefPubMedGoogle Scholar
  33. 33.
    Rutanen EM, Nyman T, Lehtovirta P, Ammala M, Pekonen F. Suppressed expression of insulin-like growth factor binding protein-1 mrna in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors. Int J Cancer 1994;59:307–312.CrossRefPubMedGoogle Scholar
  34. 34.
    Gamayunova VB, Bobrov YuF, Tsyrlina EV, Evtushenko TP, Berstein LM. Comparative study of blood insulin levels in breast and endometrial cancer patients. Neoplasma 1997;44:123–126.PubMedGoogle Scholar
  35. 35.
    Straus DS. Growth-stimulatory actions of insulin in vitro and in vivo. Endocr Rev 1984;5:356–369.CrossRefPubMedGoogle Scholar
  36. 36.
    Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol 1998;179:6–12.CrossRefPubMedGoogle Scholar
  37. 37.
    Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531–1543.PubMedGoogle Scholar
  38. 38.
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6–29.CrossRefPubMedGoogle Scholar
  39. 39.
    Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810–1812.CrossRefPubMedGoogle Scholar
  40. 40.
    Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983;61:403–407.PubMedGoogle Scholar
  41. 41.
    Dahlgren E, Friberg LG, Johansson S, Lindstrom B, Oden A, Samsioe G. Endometrial carcinoma; ovarian dysfunction—a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 1991;41:143–150.CrossRefPubMedGoogle Scholar
  42. 42.
    Ho SP, Tan KT, Pang MW, Ho TH. Endometrial hyperplasia and the risk of endometrial carcinoma. Singapore Med J 1997;38:11–15.PubMedGoogle Scholar
  43. 43.
    Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127–1135.CrossRefPubMedGoogle Scholar
  44. 44.
    Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebocontrolled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139–146.CrossRefPubMedGoogle Scholar
  45. 45.
    Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001;86:1626–1632.CrossRefPubMedGoogle Scholar
  46. 46.
    Speert, H. Carcinoma of the endometrium in young women. Surg Gynecol Obstet 1949;88:332–336.PubMedGoogle Scholar
  47. 47.
    Dockerty MB, Lovelady SB, Faust GT. Carcinoma of the corpus uteri in young women. Am J Obstet Gynecol 1951;61:966–981.PubMedGoogle Scholar
  48. 48.
    Jackson RL, Dockerty MB. The Stein Leventhal syndrome. Analysis of 43 cases with special reference to endometrial cancer. Am J Obstet Gynecol 1957;73:161–173.PubMedGoogle Scholar
  49. 49.
    Ramzy I, Nisker JA. Histologic study of ovaries from young women with endometrial adenocareinoma. Am J Clin Pathol 1979;71:253–256.PubMedGoogle Scholar
  50. 50.
    Gallup DG, Stock RJ. Adenocareinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417–420.PubMedGoogle Scholar
  51. 51.
    Escobedo LG, Lee NC, Peterson HB, Wingo PA. Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. Obstet Gynecol 1991;77:124–128.PubMedGoogle Scholar
  52. 52.
    Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow up. J Clin Epidemiol 1998;51:581–586.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Richard S. Legro
    • 1
  1. 1.Department of Obstetrics and GynecologyPennsylvania State University College of MedicineHershey

Personalised recommendations